Steven Ing, MD, Professor of Clinical Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University Wexner Medical Center, discusses three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) comparing burosumab with conventional therapy in adults with X-linked hypophosphatemia (XLH).
Understanding X-Linked Hypophosphatemia
XLH is a rare, lifelong genetic disorder that affects approximately 1 in 20,000 people. It’s caused by a genetic defect that results in excessive fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting and hypophosphatemia. In adults, XLH can cause several complications, including osteomalacia, fractures, pseudofractures, joint dysfunction, bone pain, and impaired mobility.
XLH is caused by a defect in the Phosphate Regulating Endopeptidase X-Linked gene (PHEX).
Burosumab is a monoclonal antibody administered via injection. It binds to and inhibits FGF23, helping restore phosphate levels. Burosumab received initial FDA approval in 2018 for the treatment of XLH. It has since received additional approval for the treatment of tumor-induced osteomalacia (TIO).
Three-Year Real-World Findings Compare Burosumab with Conventional Therapy
Three-year real-world findings from an interim analysis of the XLH DMP were published in the Journal of Bone and Mineral Research on September 23, 2026. DMP is a prospective, 10-year observational program enrolling adults and children with XLH in the United States, Canada, and Latin America.
The analysis included 109 adults: 54 who initiated burosumab within the first year and 55 who remained on conventional therapy, consisting of oral phosphate and active vitamin D (Pi/D). Researchers assessed serum phosphate levels and patient-reported pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
Key findings included:
- Improved serum phosphate levels
Burosumab significantly increased serum phosphate compared with conventional therapy at both years one and three. At year three, the mean change was 0.6 mg/dL with burosumab versus 0.1 mg/dL with Pi/D. Additionally, 60.8% of burosumab-treated patients achieved phosphate levels above the lower limit of normal, compared with 25% receiving conventional therapy.1
- Improvements in pain, stiffness, and physical function
Although numerical improvements were observed at year one, differences between treatment groups were not statistically significant. By year three, all three patient-reported outcomes significantly favored burosumab. Changes in pain were -9.8 versus 3.3, physical function was -10.0 versus 3.3, and stiffness was -15.2 versus -3.7.1
Clinical Implications and Future Research
Dr. Ing said that burosumab typically causes serum phosphate levels to normalize quickly, whereas improvements in other symptoms tend to take longer. He shared that current clinical practice guidelines generally recommend conventional therapy first for symptomatic adults with XLH, while burosumab is considered for intolerance or disease progression.
Dr. Ing said the three-year DMP findings suggest clinicians may want to continue treatment beyond the one-year mark and reassess its effectiveness later, as improvements in symptoms can take longer to emerge.
The XLH DMP will continue for a total of 10 years. Dr. Ing noted that future analyses will examine longer-term outcomes, including fractures and pseudofractures, nephrocalcinosis, renal function, spinal stenosis, and enthesopathy.
In Their Own Words
“The important takeaway is that burosumab will typically normalize serum phosphate levels quickly, but the associated symptoms of pain, stiffness, and physical function may take a little longer to show improvement…this study tells me to persist for longer than one year and reassess past one year.” – Steven Ing, MD, Professor of Clinical Medicine at The Ohio State University Wexner Medical Center
To learn more about XLH and other rare genetic conditions, visit https://checkrare.com/diseases/congenital-and-genetic-conditions/
Source:
